Copyright: ©Author(s) 2026.
World J Clin Oncol. Apr 24, 2026; 17(4): 119365
Published online Apr 24, 2026. doi: 10.5306/wjco.v17.i4.119365
Published online Apr 24, 2026. doi: 10.5306/wjco.v17.i4.119365
Table 1 Differences in indicator levels between healthy control group and lung cancer group
| Indicator | Healthy control group (n = 143) | Lung cancer group (n = 113) |
| CEA (ng/L) | 1.55 (0.98, 2.29) | 3.40 (1.69, 8.43) |
| CY211 (ng/mL) | 1.65 (1.22, 2.21) | 2.55 (1.76, 3.13) |
| NSE (ng/mL) | 9.46 (8.25, 10.78) | 10.79 (8.03, 12.48) |
| GM-CSF (pg/mL) | 0.72 (0.35, 1.75) | 1.42 (0.82, 2.50) |
| IL-10 (pg/mL) | 1.98 (1.16, 3.05) | 1.11 (0.81, 1.70) |
| IL-8 (pg/mL) | 17.12 (8.40, 38.69) | 315.75 (160.44, 523.19) |
| MCP-1 (pg/mL) | 341.11 (258.94, 500.58) | 636.03 (506.75, 859.70) |
| TNF-α (pg/mL) | 5.94 (4.62, 7.68) | 19.33 (12.77, 30.34) |
Table 2 Diagnostic value of carcinoembryonic antigen, cytokeratin 19 fragment, neuron-specific enolase, interleukin-8, monocyte chemoattractant protein-1, and tumor necrosis factor-alpha
| Indicator | AUC (95%CI) | P value | Cut-off value | Sensitivity (%) | Specificity (%) |
| CEA | 0.755 (0.694-0.816) | < 0.001 | 2.85 | 72.6 | 81.1 |
| CY211 | 0.703 (0.639-0.767) | < 0.001 | 2.26 | 68.1 | 74.8 |
| NSE | 0.587 (0.514-0.661) | 0.017 | 10.10 | 56.6 | 67.1 |
| IL-8 | 0.957 (0.935-0.978) | < 0.001 | 126.25 | 93.8 | 94.4 |
| MCP-1 | 0.825 (0.772-0.877) | < 0.001 | 427.64 | 86.7 | 88.1 |
| TNF-α | 0.936 (0.907-0.965) | < 0.001 | 9.85 | 89.4 | 90.9 |
Table 3 Odds ration of the indicators in the binary analysis
| Indicator | β | SE | Wals | P value | Exp(B) | 95%CI | |
| Lower | Upper | ||||||
| CEA | 0.371 | 0.135 | 7.525 | 0.006 | 1.449 | 1.112 | 1.888 |
| CY211 | 0.518 | 0.206 | 6.338 | 0.012 | 1.678 | 1.122 | 2.512 |
| IL-8 | 0.014 | 0.003 | 25.746 | < 0.001 | 1.014 | 1.009 | 1.020 |
| TNF-α | 0.100 | 0.040 | 6.125 | 0.013 | 1.105 | 1.021 | 1.196 |
- Citation: Zhang YN, Jiang T, Zhang PJ, Wang HJ. Construction and validation of a multiparameter diagnostic model based on conventional tumor markers and cytokines for lung cancer. World J Clin Oncol 2026; 17(4): 119365
- URL: https://www.wjgnet.com/2218-4333/full/v17/i4/119365.htm
- DOI: https://dx.doi.org/10.5306/wjco.v17.i4.119365
